
NEW YORK
Pfizer, one of the biggest pharmaceutical companies in the world, has taken a liking to Denmark - not just because a Dane is placed highly in the group’s global research and development department. The reason is rather that Denmark has a very developed biobank, The Danish National Biobank, which is exceedingly useful to Big Pharma players such as Pfizer which have begun focusing on gene therapy.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app